Isoliquiritigenin alleviated the Ang II-induced hypertensive renal injury through suppressing inflammation cytokines and oxidative stress-induced apoptosis via Nrf2 and NF-κB pathways

Purpose: Hypertensive renal injury plays important role in the pathogenesis of end-stage nephropathy and the need for dialysis. Isoliquiritigenin (ISL) is a natural compound with antioxidant and anti-inflammatory activities. In this study, the protective effects of ISL on Angiotensin II (Ang II)- induced apoptosis, inflammation and extracellular matrix production in HK-2 cells were observed and its mechanisms were elucidated. Methods: Cell survival was determined with MTT assay. Cell cycle and apoptosis was assessed with flow cytometric analysis. The production of cytokines including IL-1 beta and TNF-alpha were evaluated with Elisa. Western blotting assay was used to determine protein levels of apoptosis related signaling, oxidative stress, NF-kappa B and ECM related molecules. mRNA levels of fibronectin and collagen IV were detected by RT-qPCR. Results: Ang II significantly inhibited cell survival, induced cell cycle arrest and enhanced cell apoptosis. However, the above effects were markedly alleviated by ISL treatment in a dose-dependent manner. In addition, Ang II significantly induced oxidative stress and NF-kappa B signaling activation, as well as inflammatory cytokines release. In contrast, these effects were remarkably reversed by ISL via regulation of Nrf2. Notably, Ang II also triggered generation of extracellular matrix, including fibronectin and collagen IV, which was abolished upon ISL treatment. Conclusions: Taken together, ISL alleviated the Ang II-induced hypertensive renal injury through suppressing inflammation cytokines, excessive deposition of extracellular matrix and oxidative stress-induced apoptosis via Nrf2 and NF-kappa B pathways. Our findings provided the evidences for exploring the possible mechanism of hypertensive renal injury pathogenesis and identifying novel therapeutic targets. (C) 2018 Published by Elsevier Inc.